Wilmington, DE, United States of America

Glen E Ernst

USPTO Granted Patents = 15 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Wilmington, DE (US) (2005 - 2015)
Bear, DE (US) (2018 - 2024)

Company Filing History:

Lieber Institute for Brain Development

patents

3 out of 8

Lieber Institute, Inc.

patents

4. 1 out of 3,682

The Johns Hopkins University

patents

Years Active: 2005-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12234221 - Pyridine carboxamide compounds for inhibiting NAV1.8 (2025-02-25),

2. 11993581 - Pyridazine compounds for inhibiting Nav1.8 (2024-05-28),

3. 11001581 - Compounds which inhibit RNA polymerase, compositions including such compounds, and their use (2021-05-11),

4. 10934283 - COMT inhibiting methods and compositions (2021-03-02),

5. 10479790 - COMT inhibiting methods and compositions (2019-11-19),

6. 10035799 - COMT inhibiting methods and compositions (2018-07-31),

7. 9951057 - COMT inhibiting methods and compositions (2018-04-24),

8. 9035065 - Ethanamine compounds and methods of using the same (2015-05-19),

9. 8013165 - Ethanamine compounds and methods of using the same 545 (2011-09-06),

10. 7977355 - N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl (2011-07-12),

11. 7659286 - N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide (2010-02-09),

12. 7482338 - Non-amide nonanes (2009-01-27),

13. 7276528 - Compounds for the inhibition of nitric oxide synthase (2007-10-02),

14. 7119122 - Compounds for the inhibition of nitric oxide synthase (2006-10-10),

15. 6906193 - N-type calcium channel antagonists for the treatment of pain (2005-06-14),

Title: Glen E Ernst: Innovator in Pyridine and Pyridazine Compounds

Introduction

Glen E Ernst is a notable inventor based in Wilmington, DE (US), recognized for his significant contributions to the field of medicinal chemistry. With a total of 15 patents to his name, he has made strides in developing compounds that target specific ion channels associated with various medical conditions.

Latest Patents

Among his latest innovations are the Pyridine carboxamide compounds for inhibiting NaV1.8. These compounds and their associated methods aim to treat conditions, diseases, or disorders linked to increased NaV1.8 activity or expression. Additionally, he has developed Pyridazine compounds for the same purpose, further expanding the potential therapeutic applications of his research.

Career Highlights

Glen E Ernst has worked with prominent organizations such as AstraZeneca and the Lieber Institute for Brain Development. His experience in these institutions has allowed him to collaborate on groundbreaking research and contribute to advancements in the pharmaceutical industry.

Collaborations

Throughout his career, Glen has collaborated with esteemed colleagues, including James C Barrow and Yifang Huang. These partnerships have fostered a productive environment for innovation and discovery in the field of medicinal chemistry.

Conclusion

Glen E Ernst's work in developing pyridine and pyridazine compounds showcases his dedication to advancing medical science. His contributions have the potential to impact the treatment of various conditions, highlighting the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.